Resource Summary Report

Generated by NIF on Apr 18, 2025

DF/HCC Cell Manipulation Core Facility

RRID:SCR_009734
Type: Tool

Proper Citation

DF/HCC Cell Manipulation Core Facility (RRID:SCR_009734)

Resource Information

URL: http://harvard.eagle-i.net/i/0000012d-c90c-c8fc-4882-b08d80000000

Proper Citation: DF/HCC Cell Manipulation Core Facility (RRID:SCR_009734)

Description: Core facility that provides the following services: Hematopoietic progenitor cell (HPC) components processing, Tumor cell vaccine generation, Dendritic cell vaccine generation, Validation consultation.

The (Connell and O''Reilly Families) Cell Manipulation Core Facility (CMCF), at Dana-Farber Cancer Institute (DFCI) was created in 1996 to be the manufacturing facility that produces safe and effective novel cellular component therapy that meets regulatory guidelines for clinical use and also facilitates research to be translated from the bench to the bedside. The goal of this facility is to assist DF/HCC investigators in developing new cell-based therapies for cancer and to support clinical research studies designed to evaluate the toxicity and efficacy of these novel treatments. In November 2004, CMCF moved to a newly constructed 6,700 square feet facility on the third floor and ground floor of the Jimmy Fund Building (JFB) at DFCI. The new facility is dedicated to the production of clinical grade cellular products for patients who participate in clinical trials conducted by DF/HCC investigators. All procedures are performed in environmentally controlled conditions according to current Good Manufacturing Practices (cGMP) for cell and tissue processing. The third floor accommodates all of the production areas while space on the ground floor is devoted to the long-term storage of cellular products, tissues and samples in liquid nitrogen and mechanical freezers. The CMCF is available to both clinical and laboratory investigators at all DF/HCC institutions and will provide services to patients at all DF/HCC affiliated hospitals. The staff of the CMCF are committed to working with DF/HCC investigators at all levels of clinical trial development and execution, including pre-clinical development, trial design, DF/HCC and FDA review, data management, quality control, internal and external audits as well as reports and publications. The Cell Manipulation Core Facility (CMCF) has been accredited by the Foundation for the Accreditation of Cellular Therapy (FACT). The CMCF services as a

Regulatory Core for Center for Human Cell Therapy and is also a member of the Joint Program in Transfusion Medicine.

Abbreviations: DF/HCC CMCF

Resource Type: access service resource, service resource, core facility

Keywords: ex vivo genetic manipulation of cells, vaccine preparation, validation

Funding:

Resource Name: DF/HCC Cell Manipulation Core Facility

Resource ID: SCR_009734

Alternate IDs: nlx_156196

Alternate URLs: http://www.dfhcc.harvard.edu/core-facilities/cell-manipulation/, http://www.chct.org/cell-manipulation-core-facility.html

Record Creation Time: 20220129T080254+0000

Record Last Update: 20250418T055220+0000

Ratings and Alerts

No rating or validation information has been found for DF/HCC Cell Manipulation Core Facility.

No alerts have been found for DF/HCC Cell Manipulation Core Facility.

Data and Source Information

Source: SciCrunch Registry

Usage and Citation Metrics

We have not found any literature mentions for this resource.